For example, a case report of imatinib-treated GIST reported diffuse expression of CD117 and CD34 in the pre-treatment biopsy, which was completely absent in viable tumor areas following neoadjuvant imatinib therapy [55]. This evidence concerns the gene KIT and neoplasm.